You are here:
CARCINOGENIC POTENTIAL OF ROTENONE. PHASE II: ORAL AND INTRAPERITONEAL ADMINISTRATION TO RATS
Citation:
Leber, A. AND D. Thake. CARCINOGENIC POTENTIAL OF ROTENONE. PHASE II: ORAL AND INTRAPERITONEAL ADMINISTRATION TO RATS. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/1-79/004B.
Description:
In the intraperitoneal study, test groups of male and female Sprague-Dawley rats were given daily doses of 0,1.7 or 3.0 mg/kg of rotenone for 42 days. The high rotenone dosage groups showed decrease in weight gain but there was no effect on mortality. There were numerous mammary gland neoplasms, mostly fibroadenomas, detected but they occurred with similar frequency among control and treatment groups. Except for two lymphosarcomas which occurred in high dose females, all other neoplasms were rare and/or not dosage related. In the oral study, groups of male and female Wistar rats were given daily doses of 0, 1.7 or 3.0 mg/kg of rotenone by gavage for 42 days. There were no appreciable effects of rotenone dosage on body weight, mortality, or non-neoplastic disease. Ductal ectasias and cysts were slightly more prevalent in mammary glands of dosed females as compared to controls. There was no evidence from either the intraperitoneal or oral project that rotenone induced mammary neoplasia in the rat strains studied. The significance of the slight increases in fibrosarcomas and fibromas in both the intraperitoneal and oral studies and in adrenal cortical adenomas in the oral study was inconclusive.